Pure Global

Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma - Trial NCT04480099

Access comprehensive clinical trial information for NCT04480099 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ruijin Hospital and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 106 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04480099
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT04480099
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
The Efficacy and Safety of Targeted Drug in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma

Study Focus

CHOP for 6 cycles

Interventional

drug

Sponsor & Location

Ruijin Hospital

Shanghai, China

Timeline & Enrollment

Phase 2

Jun 20, 2020

Jun 20, 2024

106 participants

Primary Outcome

Complete response rate

Summary

This prospective，multi-center，open-label, controlled study will evaluate the efficacy and
 safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral
 T-cell lymphoma.

ICD-10 Classifications

Peripheral T-cell lymphoma, not elsewhere classified
Cutaneous T-cell lymphoma, unspecified
Mature T/NK-cell lymphomas
Angioimmunoblastic T-cell lymphoma
Other mature T/NK-cell lymphomas

Data Source

ClinicalTrials.gov

NCT04480099

Non-Device Trial